Mavenir Launches Open RAN Intelligent Controller (O-RIC) Offering Enabling Service Differentiation and Network Resource Optimization
Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, today announced the availability of its O-RAN alliance Radio Access Network Intelligent Controller (RIC), a next-generation network intelligence offering for Open RAN. Mavenir O-RIC enables the creation of differentiated services through open APIs, which enable intelligent closed-loop end-to-end network tuning to optimize network performance, increase cost efficiency and maximize the user experience. Mavenir’s O-RIC offers Network Intelligence as a Service (NIaaS) that provides deep, fine-grained insights about the network and enables building solutions with advanced state of art intelligence. Open RAN networks can also now generate new class-of-service revenue streams by adaptively reacting in near-real time to dynamic changes in network, traffic, and load patterns. Mavenir’s O-RIC is currently in deployment with two, tier one Communications Service Providers (CSPs).
Traditional RAN networks currently use area wide Self-Organizing Network (SON) models for exercising Radio Resource Management (RRM) and configuration management optimization decisions at a per-cell level. They rely on single control loop, leverage key performance indicators (KPIs) and analytics for such control decisions at non-real time (Non-RT) granularities.
Mavenir’s O-RIC surpasses the capabilities of SON with two control loops:
- Non-RT O-RIC — Typically deployed in a centralized cloud, it builds advanced Machine Learning (ML) algorithms using long-term RAN data to define dynamic and adaptive policies to control and optimize network performance and configuration management decisions. Non-RT RIC can also be used in existing legacy networks, adding another performance layer through ML for policy control.
- Near-real time (Near-RT) O-RIC — Deployed at or towards the edge, it uses a low latency control loop that optimizes RAN activity at both the cell and individual user equipment (UE) level by hosting trained Artificial Intelligence (AI) and ML applications to infer and control Open RAN elements in near-RT. The near-RT O-RIC intelligently optimizes UE-level control-plane call processing and user-plane data transfer decisions. This level of granularity is not available in SON.
Mavenir’s O-RIC is a business results tool, that enables intent-based decisions by setting granular performance targets—at the cell or even individual UE level—to generate business outcomes, such as the generation of additional revenue (enabling an SLA that generates a premium service), the reduction in network cost through the optimization of resources (energy savings, spectral efficiency, etc.), or the improvement of the end user experience (by improving throughput, reducing latency and connection drops, and expanding coverage). The NIaaS signature framework of Mavenir’s RIC accomplishes this goal by offering fine-grained predictive intelligence and advanced analytics about the RAN to third party applications (rApps and xApps), integrated with Mavenir’s O-RIC, towards optimizing the network performance.
Mavenir’s O-RIC shifts control from the vendor ecosystem to the operator by delivering an Open API framework that allows the implementation of standards-based rApps and xApps for different business outcomes, such as energy savings, traffic steering, massive MIMO optimization, spectral efficiency improvements, and RAN slice assurance. Proprietary radio access solutions limit the choice to what their vendor has to offer and open up the network to fine-grained per user data-driven optimization. With Mavenir’s RIC, applications can be developed by an in-house team or purchased in an "app store" from any Open RAN compliant third party.
"Creating real business value for next-generation Open RAN networks requires deep telco domain expertise and a disruptive approach to network intelligence," said Brandon Larson, SVP & GM of the Multimedia Business Unit at Mavenir. "As a pioneer in cloud-native solutions at a massive scale, Mavenir is leading the way with award-winning Open vRAN solutions, layered with O-RIC AI and ML algorithms and applications, which create operator customizable business outcomes based on target objectives to solve unique business problems and give control of the network back to the CSP."
Mavenir's O-RIC offers unparalleled benefits in terms of (i) Network performance, (ii) User Experience, (iii) Reduced TCO, (iv) Simplified cloud-native deployments, (v) new revenue sources, etc.
For more information visit the Mavenir Open RAN Intelligent Controller page.
Mavenir is exhibiting at Mobile World Congress 2023 in Barcelona, Spain at the Fira Gran Via in Hall 2, stand 2H60. Click here to find out more.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230210005022/en/
Contact information
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
